|Videos|January 31, 2019
Overcoming Acquired Resistance Mechanisms in BRAF+ mCRC
Advertisement
Episodes in this series
Following their discussion on data from the BEACON and ANCHOR trials, experts look towards the future and the potential of overcoming acquired resistance mechanisms in the treatment of BRAF-mutated metastatic colorectal cancer.
Advertisement
Related to this article
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Read a refresh of GI cancer FDA news from August 2026, including the approval of a RAS(ON) inhibitor in metastatic pancreatic cancer.
The estimated 3-year OS rate with botensilimab plus balstilimab was 48% in heavily pretreated recurrent ovarian cancer in the phase 1b C-800-01 trial.
Japan approved Optune Pax plus gemcitabine and nab-paclitaxel for unresectable locally advanced pancreatic cancer.
A New England Journal of Medicine report describes complete hepatoblastoma regression in a 3-year-old treated with a novel immunotherapy.
Benjamin Weinberg, MD, discusses the FDA approval of daraxonrasib, RASolute 302 survival data, safety considerations, and future RAS-targeted therapies in pancreatic cancer.
The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
INBRX-106 Plus Pembrolizumab Improves Responses and PFS in First-Line PD-L1–Positive HNSCC
2
Epcoritamab Plus R-CHOP Meets PFS End Point in Newly Diagnosed DLBCL
3
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
4
‘Our Impact Will Be Broad and Transformative’: Wells Messersmith, MD, Takes the Reins at CU Anschutz Cancer Center
5